Lipid profile in type 2 diabetic subjects aged 40 years and over living in Benin

Casimir D. Akpovi*, Segbo A.G. Julien, Medehouenou T.C. Marc, Anago A.A. Eugénie, Akakpo B. Huguette and Frédéric Loko

Department of Human Biology Engineering, Research Laboratory in Applied Biology, Polytechnic School of Abomey-Calavi, University of Abomey-Calavi, Benin.

*Correspondence Info:
Dr. Casimir D. Akpovi,
Department of Human Biology Engineering,
Polytechnic School of Abomey-Calavi,
University of Abomey-Calavi,
01 Po. Box 2009 Cotonou, Republic of Benin.
E-mail: casiom@yahoo.fr

Abstract

Background: Abnormal lipid profile is common in subjects with type 2 diabetes (T2D). Despite use of lipid-lowering agents, many subjects with T2D do not achieve lipid targets. The present work aimed to assess lipid profile in a randomly selected group of adult diabetic subjects under treatment in order to determine how diabetes treatment affects blood lipid parameters levels. HbA1c level is used as a biomarker of glycaemia control achievement and treatment success in diabetic.

Methods: This study was carried out as a pre-post test design study with a control group. A total of 117 diabetic subjects under treatment and 100 non-diabetics as control subjects are included in the study. TC, TG and HDL-C were measured by enzymatic methods and LDL-C was determined by Friedewald formula. Plasma glucose was measured by Glucose Oxidase method and glycated hemoglobin (HbA1c) with a radioimmunoassay.

Results: The results showed that TC (p<0.001), LDL-c (p<0.001) and TG (p=0.02) levels increased significantly in diabetics compared to controls. Atherogenic indices TC/HDL-C (p<0.01) and LDL-C/HDL-C (p<0.01), and blood calcium level (p<0.001) were significantly increased in diabetics than in controls. Subjects with HbA1c value >7.0% had significantly higher levels of TC (P<0.01), LDL-C (p<0.05), TC/HDL-C (p<0.01), LDL-C/HDL-C (p=0.02), TG/HDL-C (p=0.01) and calcemia (p<0.001) compared to subjects with HbA1c ≤7.0%.

Conclusion: Significant difference of lipid parameters was observed in diabetics with HbA1c ≤7.0% and >7.0%. Abnormal lipid patterns and insulin resistance tend to be normalized with therapy of diabetes.

Keywords: Type 2 diabetes, HbA1c, lipid parameter, insulin resistance, Benin

1. Introduction

Type 2 Diabetes (T2D) is a hereditary, chronic and endocrine metabolic disorder which causing deaths worldwide [1]. Its prevalence is on rising in developing countries [2,3]. Due to genetic disposition and life style, certain ethnic and racial groups, especially in Africa and Asia, have a greater risk of developing diabetes [4]. The chronic hyperglycaemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, such as the eyes, kidneys, nerves, heart, and blood vessels [5]. Glycated hemoglobin (HbA1c) is a routinely used biomarker for long-term glycemic control. Diabetes treatment is adjusted based on the HbA1c results, expressed as the percentage of hemoglobin that is glycated. A vast majority of assays have been standardized worldwide through the National Glyco-hemoglobin Standardization Program [6] that established the relationship between HbA1c levels and risk for long-term diabetes complications. Nigeria, the most populous country in Africa, is reported to harbour a substantial number of individuals living with diabetes [7]. Abnormal lipid profile is reported tightly associated with diabetes complications in Nigeria [8]. In Benin, which is a close country of Nigeria, little is known about lipid and diabetes association in diabetes suffering population.

Abnormal lipid profile is more common in diabetes and is aggravated with a poor glycaemia control. Then the determination of lipid profile in diabetic subjects is required to investigate how lipid metabolism is affected by diabetes per se and its
treatment. The present work aimed to assess lipid profile in a randomly selected group of adult diabetic subjects under treatment in order to determine how diabetes per se and its treatment affect blood lipid parameters levels. HbA1c level is used as a biomarker of glycaemia control achievement and treatment success in diabetic subjects.

2. Material and methods

2.1 Study participants

This study was carried out as a pre-post test design study with a control group at Hôpital Saint-Jean (Cotonou, Benin). From March 2014 to August 2015, a total of 117 subjects (49 females and 68 males) suffering from diabetic and visiting the hospital were enrolled in the study. All diabetic subjects were under treatment and were aged 40 years and over. Diabetic subjects aged less than 40 were excluded from the study. One hundred (100) age- and sex-matched healthy subjects with no complaints and no known diseases were randomly selected at the same hospital and enrolled as control group. Laboratory tests were used to confirm the absence of diabetes in the control group and also by asking questions about signs of diabetes such as polyuria, polydipsia and recent weight loss. Informed consent was voluntarily obtained from each participant before entering the study and the local research ethics board approved the study protocol.

2.2 Measurement of Biochemical Parameters

Venous blood samples were collected from all the individuals after at least 8 hours fasting. The samples were centrifuged and serum fasting blood glucose concentrations were measured within 30min to 1h following blood samples collection. Plasma glucose was measured by Glucose Oxidase and Peroxidase (GOD-POD) method (ELITech Group, Puteaux, France) according to the manufacturer’s instructions. Blood samples for HbA1c were obtained at baseline. HbA1c levels were measured with a radioimmunoassay (Roche HbA1c and Roche Tinaquant; Roche Diagnostics, Meylan Cedex, France). TC (ELITech Group, Maizy, France), high density lipoprotein cholesterol (HDL-C) (Biolabo, Maizy, France) and TG (ELITech Group, Maizy, France) were assayed by enzymatic methods. Low density lipoprotein cholesterol (LDL-C) was determined using the Friedewald’s formula LDL-C = TC – (HDL-C - TG/5) when TG values were under 400 mg/dl. According to National Cholesterol Education Programme (NCEP) Adult Treatment Panel III (ATP III) guideline [9], hypercholesterolemia is defined as TC >200 mg/dl, high LDL-C when value >100 mg/dl, hyper-triglyceridemia as TG >150 mg/dl and low HDL-C when value <40 mg/dl.

2.3 Statistical analyses

Data were analysed by SigmaPlot statistical analysis software 2010 (Systat Software, Inc. San Jose, CA, USA). Means and standard errors of the mean (SEM) of blood parameters were calculated. Student’s t-test was used to ascertain any difference between the group characteristics. A p value of < 0.05 was deemed significant.

3. Results

3.1 Clinical characteristics of the study subjects

Table 1 shows demographic data of subjects and control participants. The mean (SEM) age of the study subjects was 51.40 (8.30) years for controls and 57.05 (6.05) years for diabetic subjects. Ages were ranged from 40–84 years for both groups. Women represent 43% of the controls and 49% of diabetic subjects. The BMI level in control participants (27.5 kg/m$^2$ ± 3.7) was significantly different from the level in diabetic subjects (31.0 kg/m$^2$ ± 9.1). Average duration of diabetes was 3 years, ranged from 11 months to 15 years.

| Table 1: General characteristic of type 2 diabetic Subjects and in controls |
|--------------------------|-----------------|------------------|
| Characteristics          | Diabetics (n=117) | Controls (n=100) |
| Age (years)              | 57.05 ± 6.05     | 51.40 ± 8.30     |
| Women (%)                | 49               | 43               |
| BMI (kg/m$^2$)           | 31.0 ± 9.1       | 27.5 ± 3.7       |

3.2 Lipid abnormalities

Biochemical parameter levels are shown in table 2. Blood glucose level was significantly (p<0.001) higher in diabetics (1.89 ± 0.09 g/l) compared to controls (0.80 ± 0.03 g/l). Like glycaemia, HbA1c level was significantly higher (p<0.001) in diabetic subjects (9.34 ± 0.21%; ranged from 3.92% to 14.51%) compared to 4.44 ± 0.10% in controls (ranged from 4.63% to 5.80%). However, no strong correlation between glycaemia and HbA1c in diabetic was observed (Fig. 1). Diabetics have significantly higher TC (p<0.001), TG (p=0.02) and LDL-C levels (p<0.001) compared to non-diabetic. HDL-C level in diabetics was not significantly (p=0.86) different from that in non-diabetic subjects. Among all the lipid parameters, only LDL-C level was beyond reference value in diabetics (124.94 mg/l vs. 100 mg/l). We calculated atherogenic indices in order to determine how these predictors of disease are associated with dyslipidemia in T2D subjects.
TC/HDL-C (p<0.01) and LDL-C/HDL-C (p<0.01) in diabetics were significantly increased compared to non-diabetic subjects. TG to HDL-C ratio, which is considered as reliable as fasting serum insulin levels, was determined to assess insulin resistance statute in diabetic subjects [25]. TG/HDL-C ratio was significantly (p<0.001) higher in diabetics than in controls. Blood calcium level was significantly (p<0.001) higher in diabetics than in controls while magnesium level showed no significant difference (p=0.12).

**Table 2: Biochemical parameters in Type 2 Diabetic Subjects and in controls**

| Parameters                  | Reference range | DT2 (n=117)       | Controls (n=100) | p-Value  |
|-----------------------------|-----------------|-------------------|------------------|----------|
| Glucose (g/l)               | 0.65-1.10       | 1.89 ± 0.09       | 0.80 ± 0.03      | < 0.001  |
| HbA1c (%)                   | 4-6             | 9.34 ± 0.21       | 4.44 ± 0.10      | < 0.001  |
| TC (mg/dl)                  | < 200           | 198.09 ± 46.30    | 141.52 ± 6.78    | < 0.001  |
| Triglycerides (mg/dl)       | < 150           | 112.50 ± 5.95     | 81.48 ± 8.76     | 0.02     |
| HDL-C (mg/dl)               | > 40            | 49.58 ± 1.97      | 48.78 ± 4.60     | 0.86     |
| LDL-C (mg/dl)               | < 100           | 124.94 ± 5.00     | 76.44 ± 6.02     | < 0.001  |
| TC/HDL-C                    | < 5             | 4.63 ± 0.20       | 3.51 ± 0.35      | 0.01     |
| LDL-C/HDL-C                 | < 3.5           | 3.04 ± 0.16       | 1.96 ± 0.24      | < 0.01   |
| TG/HDL-C                    | nd              | 3.11 ± 0.28       | 1.75 ± 0.15      | < 0.001  |
| Calcium (mg/l)              | 90-105          | 89.28 ± 3.20      | 107.58 ± 1.04    | < 0.001  |
| Magnesium (mg/l)            | 16-25           | 17.83 ± 6.89      | 19.23 ± 0.28     | 0.13     |

*nd: non determined*

**Figure 1: Correlations between HbA1c and glycaemia in diabetic subjects.**

To determine how glycaemia control achievement affect biochemical parameters, diabetic subjects were classified into 2 groups. First group consists of subjects with HbA1c value ≤7.0% and second group consists of subjects with HbA1c value >7.0%. The results are shown in table 3. Subjects with HbA1c value >7.0% had significantly higher value of blood glucose (p<0.001), TC (p<0.01), HDL-C (p<0.01), and LDL-C (p<0.05). TG (p=0.17) level showed no significant changes. Both TC/HDL-C (p<0.01) and LDL-C/HDL-C (p=0.02) levels were significantly (p<0.001) higher in diabetic with HbA1c value >7.0% compared to subjects with HbA1c ≤7.0%. TG/HDL-C level was significantly (p<0.01) higher in case of HbA1c value >7.0% compared to when HbA1c ≤7.0%. Blood calcium level also varied in diabetic population. Calcemia level, which was lower in diabetic subject than in controls, decreased even further in diabetic subjects with HbA1c value >7.0% compared to subjects with HbA1c ≤7.0% (p<0.01). Blood magnesium level showed no significant changes between both groups of diabetic subjects.
Table 3: Biochemical Parameters categorized by subjects' glycemic controls (HbA1c)

| Parameter         | Glycated Hemoglobin (HbA1c) | P-value |
|-------------------|-----------------------------|---------|
|                   | ≤ 7.0 (n=100)               | > 7.0 (n=117) |         |
|                   | Mean ± SEM                  | Mean ± SEM |         |
| Glucose (g/l)     | 1.27 ± 0.19                 | 2.05 ± 0.10 | < 0.001 |
| TC (mg/dl)        | 173.98 ± 11.50              | 203.03 ± 9.56 | 0.01    |
| Triglycerides (mg/dl) | 97.00 ± 8.95           | 117.00 ± 7.03 | 0.17    |
| HDL-C (mg/dl)     | 51.46 ± 5.40                | 37.49 ± 2.21 | < 0.01  |
| LDL-C (mg/dl)     | 105.15 ± 10.48              | 131.14 ± 5.45 | < 0.05  |
| TC/HDL-C          | 3.63 ± 0.28                 | 4.84 ± 0.23 | 0.01    |
| LDL-C/HDL-C       | 2.23 ± 0.21                 | 3.63 ± 0.19 | 0.02    |
| TG/HDL-C          | 2.80 ± 0.21                 | 4.73 ± 0.30 | 0.01    |
| Calcium (mg/l)    | 95.42 ± 6.17                | 84.22 ± 1.53 | 0.001   |
| Magnesium (mg/l)  | 18.53 ± 1.81                | 16.87 ± 0.37 | 0.07    |

4. Discussion

The determination of serum lipid parameters is required in diabetic subjects care. To understand the mechanism underlines the changes in lipoproteins in diabetes mellitus and the way by which this may influence the development of the cardiovascular disease that accompanies this disorder, we examine the metabolism of lipoproteins. Screening and treatment of lipid abnormalities prevents and reduce the risk of cardiovascular events [10-12]. However, lipid profile determination is not a routine exam in diabetic treatment monitoring in Benin. The present work aimed to assess lipid profile in a randomly selected group of adult diabetic subjects under treatment in order to determine how diabetes per se and its treatment affect blood lipid parameters levels. HbA1c level is used as a biomarker of glycaemia control achievement and treatment success in diabetic subjects.

Diabetes is a chronic disease whose complications appear only after several years. By conducting this study in diabetics aged 40 years and over, we hoped to achieve explicit outcomes. We measured the serum levels of TC, TG, HDL-C and LDL-C in diabetics subjects that we compared to those from non-diabetic subjects. A total of 217 subjects participated to the study including 117 with T2D and 100 non diabetic subjects as the control group. The group of diabetic subjects was equally composed of women and men. Diabetic subjects were predominantly overweight (83%). This result is far higher than the average proportion of overweight or obese in West Africans which were estimated at 31.4% [13]. Obesity is an additional risk factor for diabetes [14] and our finding relative to the high rate of overweight in diabetics is of paramount concern.

The results of HbA1c are very revealing. In the control group, the values were from 4.0 to 5.0% and no diabetic had HbA1c result <7.0%. Many diabetics had blood sugar in the normal range and the correlation between blood glucose and HbA1c in diabetics was of poor quality. This suggests that blood sugar is not a good biomarker in diabetics. HbA1c level has been suggested to be used for the diagnosis of diabetes [1]. Our results strongly support this idea. For this purpose, Mayer and Schriger [15] reported that whether an individual has an initial HbA1c level of ≥7.0% but on a repeat test has a level <7.0%, the diagnosis should be pre-diabetes. These individuals should be treated appropriately and periodically retested to ensure that their HbA1c level remains below 7.0%.

It is known that subjects with diabetes can have many complications including elevated levels of VLDL-C, LDL-C and TG, and low levels of HDL-C [16]. In the present study, the results showed that lipid parameters TC, TG, LDL-C levels of the diabetics were higher than those in the controls. Our results are in agreement with other findings [8,17] but with somewhat less profound lipid profile damage. This difference could be explained by the fact that diabetics in our sample were under treatment. Among all the lipid parameters, only LDL-C level was beyond reference value in diabetics. Elevated LDL-C is a major risk factor for cardiovascular disease [18]. As such, management of LDL-C is the primary goal of therapy for diabetic dyslipidemia [19,20].

Atherosclerosis and cardiovascular disease are common in clinical cases where dyslipidemia is present. We estimated the atherogenic indices TC/HDL-C and LDL-C/HDL-C in order to determine whether diabetics were at risks of cardiovascular diseases. Our results showed that the atherogenic indices were higher in diabetics than in controls. However, these levels were within the normal ranges [9] suggesting that diabetics in our study were at low risk of cardiovascular disease and that the fundamental of their treatment is good. Our finding that blood Ca²⁺ level is low in diabetics compared to
controls is in agreement with the report that this ion plays important role in insulin secretion [21], and that insulin level must be decreased in diabetics [22].

HbA1c was established as the gold standard of glycemic control. The level of HbA1c value ≤7.0% was said to be appropriate for reducing the risk of cardiovascular complications [23]. In the present study, we determined that diabetics with HbA1c value >7.0% had worsen lipid profile compared to diabetics with HbA1c ≤7.0%. As elevated HbA1c and dyslipidemia are independent risk factors of cardiovascular disease, diabetic subjects with elevated HbA1c and dyslipidemia can be considered at higher risk group for cardiovascular disease [24]. Our finding that both atherogenic indices TC/HDL-C and LDL-C/HDL-C were significantly increased and beyond references values is in accordance with the notion that bad glycemia control augment complication and cardiovascular disease risks in diabetics [23,24]. It was reported that a simple TG/HDL-C ratio is a good marker of insulin resistance [25]. Insulin resistance is the basic pathology underlying type 2 diabetes. Here, we showed that TG/HDL-C level was increased in diabetic than in controls and in diabetic with HbA1c >7.0% compared to diabetics with HbA1c ≤7.0%. Our results support the notion that TG/HDL-C ratio can be used as a surrogate of insulin resistance [25] and that HbA1c level control under treatment reflects insulin resistance improvement.

5. Conclusion

Plasma TC and TG are significantly elevated in diabetics compared to non-diabetics. Significant difference of lipid parameters was observed in diabetics with HbA1c ≤7.0% and >7.0% confirming that HbA1c can be used as a potential biomarker for predicting dyslipidemia in T2D subjects. Abnormal lipid patterns and insulin resistance tend to be normalized with therapy of diabetes.

References

[1] Davidson MB, Peters AL, Schriger DL. An alternative approach to the diagnosis of diabetes with a review of literature. Diabetes Care 1995; 18: 1065-1701.

[2] Bennett PH. Epidemiology of type 2 diabetes mellitus in: Diabetes Mellitus. Lekoith D, Taylor SI, Olefsky JM. (eds.) 2 nd ed. Wolter, New York; 2000. p. 544-57.

[3] Sajjadi F, MohammadiFard N, Ghaderian N, Alikhasi H, Maghroon M. Clustering of cardiovascular risk factors in diabetic and IGT cases in Isfahan province. 2000-2001: Isfan healthy heart program. Arty J 2005; 1: 94-100.

[4] Manu A, Shyamal K, Sunil G, Sandhu JS. A study on lipid profile and body fat in patients with diabetes mellitus. Anthropologist 2007; 4: 295-298.

[5] Baynes JW, Thorpe SR. The role of oxidative stress in Diabetic complications of diabetes. Curr Opin Endocr 1996; 3: 277- 284.

[6] Little RR, Rohlifing CL, Wiedmeyer H-M, Myers GL, Sacks DB, Goldstein DE. The National Glycohemoglobin Standardization Program: a 5-year progress report. Clin Chem 2001; 47:1985–1992.

[7] Ugwu CE, Ezeanyika LUS, Daikwo MA, Amana R. Lipid profile of a population of diabetic patients attending Nigerian National Petroleum Corporation Clinic, Abuja. African Journal of Biochemistry Research 2009; 3: 66-69.

[8] Idogun ES, Unuigbe E.I, Ogunro PS, Akinola OT, Famodu, AA. Assessment of serum lipids in Nigerians with type 2 diabetes mellitus complications. Pak J Med Sci (Part 1) 2007; 23: 708-712.

[9] National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

[10] Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in noninsulin-dependent diabetes mellitus. Ann Med 1996; 28: 341-5.

[11] Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care. 1999; 22: 14-20.

[12] Yach D, Hawkes C, Gouuld CL, Hofman KJ. The Global Burden of Chronic Diseases. Overcoming the impediments to prevention and control. JAMA 2004; 291: 2616-22.

[13] Ziraba AK, Fotso JC, Ochako R. Overweight and obesity in urban Africa: A problem of the rich or the poor? BMC Public Health 2009; 9: 465-474.

[14] Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997; 146: 214-22.

[15] Mayer BD, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: Implications for the diagnosis of diabetes. Diabetes research and clinical practices 2010; 87:415-21.

[16] Haffner SM. Management of dyslipidaemia in adults with diabetes. Diabetes Care 1998; 21: 160-178.
[17] Albrki WM, Elzouki ANY, EL-Mansoury ZM, Tashani OA. Lipid profiles in Libyan type 2 diabetes. J Sci Appls 2007; 1: 18-23.

[18] Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BM J 1998; 316: 823-28.

[19] Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuh S, Probstfield JL, Simons-Morton DG. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 4i-20i.

[20] Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL: Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811-22.

[21] Jones PM, Persaud SJ, Howell SL. Time-course of Ca2+-induced insulin secretion from perifused, electrically permeabilised islets of Langerhans: effects of cAMP and a phorbol ester. Biochem Biophys Res Commun 1989; 162: 998-1003.

[22] Alsahl M, Gerich JE. Abnormalities of insulin secretion and beta-cell defects in type 2 diabetes. Textbook of Diabetes 4th edition, 2010.

[23] Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications trial. Diabetes Care 2002; 25: 275-8.

[24] Mahato Vinod Ram, Prajwal Gyawali, Pramod Psd. Raut, Prashant Regmi, Khelanand Psd. Singh, Dipendra Raj Pandeya, Prabin Gyawali. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. Biomedical Research 2011; 22: 375-80.

[25] Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Koyama H, Shoji T, Inaba M, Nishizawa Y. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. J Clin Endocrinol Metab 2004; 89: 1481-4.